April 18, 2024

• 

In addition to the success of Remsima, its anti-cancer biosimilar Truxima is expanding market share in Europe at an even faster pace beating the glum forecasts that doctors will be more selective for cancer treatments and that it is an IV injection formula. Truxima’s European market share has risen as high as 35 percent by the end of first quarter, from 18 percent as of end-2017, said analyst Han Byeong-hwa

The outlook for Herzuma and Truxima’s introduction in the US also is rosy. Although the US Food and Drug Administration has requested improvements in manufacturing facilities, they are likely to obtain approval by the end of this year. The success of Remsima, Truxima and Herzuma has propelled the company’s stock price rise and in the future Remsima’s SC formula will take over the role, said the analyst, adding that the formula will be launched in Europe next year and in the US by 2020. 

By Hwang You-mee (glamazon@heraldcorp.com)